This article discusses the risks of patient harm in psychedelic therapy and the unsettling revelation of misconduct allegations against a prominent figure.
The article explores the question of whether MDMA is a psychedelic drug. Research suggests that MDMA, while not producing trippy visuals, can impact brain connectivity similarly to hallucinogenic substances like LSD. Ultimately, the characterisation of MDMA as a psychedelic depends on the context.
Two Australians have recently become the first in the country to undergo psychedelic medicine treatment. This significant milestone follows the Therapeutic Goods Administration's decision to reclassify MDMA and Psilocybin. Despite accessibility challenges, this development provides hope for those seeking alternative treatments.
A personal account of the first steps of someone's journey trying to access psychedelic therapy
Unworkable regulatory conditions prevent practitioners from providing psychedelic-assisted therapy to the public